- Home
- ILAG vs JAGX Comparison
ILAG vs JAGX Comparison
Compare ILAG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- JAGX
- Stock Information
- Founded
- ILAG 1981
- JAGX 2013
- Country
- ILAG Hong Kong
- JAGX United States
- Employees
- ILAG N/A
- JAGX N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- JAGX Health Care
- Exchange
- ILAG Nasdaq
- JAGX Nasdaq
- Market Cap
- ILAG 14.4M
- JAGX 12.9M
- IPO Year
- ILAG 2022
- JAGX N/A
- Fundamental
- Price
- ILAG $0.83
- JAGX $0.86
- Analyst Decision
- ILAG
- JAGX
- Analyst Count
- ILAG 0
- JAGX 0
- Target Price
- ILAG N/A
- JAGX N/A
- AVG Volume (30 Days)
- ILAG 12.4K
- JAGX 311.0K
- Earning Date
- ILAG 04-14-2025
- JAGX 03-31-2025
- Dividend Yield
- ILAG N/A
- JAGX N/A
- EPS Growth
- ILAG N/A
- JAGX N/A
- EPS
- ILAG N/A
- JAGX N/A
- Revenue
- ILAG $8,980,747.00
- JAGX $10,480,000.00
- Revenue This Year
- ILAG N/A
- JAGX $18.18
- Revenue Next Year
- ILAG N/A
- JAGX $40.06
- P/E Ratio
- ILAG N/A
- JAGX N/A
- Revenue Growth
- ILAG 33.03
- JAGX N/A
- 52 Week Low
- ILAG $0.35
- JAGX $0.78
- 52 Week High
- ILAG $1.35
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- ILAG 49.70
- JAGX 45.91
- Support Level
- ILAG $0.73
- JAGX $0.78
- Resistance Level
- ILAG $0.84
- JAGX $1.03
- Average True Range (ATR)
- ILAG 0.08
- JAGX 0.07
- MACD
- ILAG 0.01
- JAGX 0.01
- Stochastic Oscillator
- ILAG 79.70
- JAGX 30.44
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.